Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 17
226
Views
1
CrossRef citations to date
0
Altmetric
Short Communications

Synergistic protective effect of Camellia sinensis leaf buds and Camellia sinensis flowers against cisplatin-induced nephrotoxicity in rats and characterization of its bioactive compounds

, ORCID Icon, &
Pages 4464-4468 | Received 20 Jul 2021, Accepted 15 Sep 2021, Published online: 29 Sep 2021
 

Abstract

An effective antitumor drug like cisplatin has toxic effects leading to kidney injury. The authors investigated the nephroprotective action of C. sinensis leaf buds (CSB) and its flowers (CSF), both individually and in combined therapy against cisplatin-induced renal injury. Renal functional tests, oxidant, anti-oxidant and histopathology of kidney tissues are assessed. The major findings of the experiment is that the CSB and/or CSF ameliorate the successive conditions of (1) Renal dysfunction (Serum creatinine, urea, uric acid and glucose, protein level present in the urine) (2) The degree of lipid peroxidation (3) Antioxidant enzyme suppression and (4) The destructive renal architecture associated with drug-induced renal toxicity. Result suggests that the combined therapy of CSB and CSF was highly effective when compared to monotherapy in the complete regeneration of destructive cells by drug effect and could be an addition of a new source to the pharmaceutical industry as antioxidant nutrition supplement

Graphical Abstract

Acknowledgments

The authors would like to acknowledge Dr. Viswanathan for his guidance throughout the study.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.